Want to see IN:AUROPHARMA full AI Analyst Report?
AUROPHARMA Stock Chart & Stats
₹1622.00
₹17.40(1.14%)
At close: 4:00 PM EDT
₹1622.00
₹17.40(1.14%)
Day’s Range― - ―
52-Week Range₹1,017.00 - ₹1,682.00
Previous CloseN/A
Volume850.22K
Average Volume (3M)40.80K
Market Cap
₹922.47B
Enterprise Value₹731.37K
Total Cash (Recent Filing)₹105.85B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)25.4
Beta0.65
Next Earnings
Nov 09, 2026EPS Estimate
19.11Next Dividend Ex-DateN/A
Dividend Yield0.25%
Share Statistics
EPS (TTM)64.00
Shares Outstanding575,377,870
10 Day Avg. Volume31,329
30 Day Avg. Volume40,801
Financial Highlights & Ratios
PEG Ratio24.40
Price to Book (P/B)2.00
Price to Sales (P/S)2.25
P/FCF Ratio26.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)79.45
Revenue Forecast (FY)₹400.47B
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthConsistent revenue expansion indicates durable demand across Aurobindo Pharma’s diversified generic formulations and API businesses. Continued growth supports manufacturing utilization, market presence, and the company’s ability to build scale across domestic and regulated international markets.
Conservative LeverageImproving leverage and a growing equity base strengthen financial resilience. Lower debt dependence gives Aurobindo greater flexibility to fund manufacturing capacity, product development, regulatory requirements, and working capital while reducing balance-sheet risk through industry cycles.
Improved Free Cash FlowThe return to substantial positive free cash flow improves the company’s ability to self-fund capital expenditure, debt reduction, and product investments. Stronger cash generation can support long-term pharmaceutical capacity expansion without relying heavily on external financing.
Bears Say
Margin CompressionThe sharp gross-margin decline indicates that revenue growth is facing pressure from product mix, pricing, input costs, or competitive intensity. If sustained, lower margins could restrict reinvestment capacity and weaken the earnings benefit of expanding pharmaceutical sales.
Flat Net IncomeLimited earnings progression suggests that topline expansion is not consistently converting into shareholder profit. Persistent stagnation could constrain retained capital, reduce the payoff from scale investments, and signal that operating or cost pressures are offsetting commercial growth.
Moderate Returns And Cash ConversionModerate ROE shows that profitability relative to the enlarged equity base has softened. Although cash flow improved in 2026, historically negative free cash flow and modest operating-cash conversion indicate that earnings may not consistently translate into deployable cash.
Aurobindo Pharma Ltd News
AUROPHARMA FAQ
What was Aurobindo Pharma Ltd’s price range in the past 12 months?
Aurobindo Pharma Ltd lowest stock price was ₹1017.00 and its highest was ₹1682.00 in the past 12 months.
What is Aurobindo Pharma Ltd’s market cap?
Aurobindo Pharma Ltd’s market cap is ₹922.47B.
When is Aurobindo Pharma Ltd’s upcoming earnings report date?
Aurobindo Pharma Ltd’s upcoming earnings report date is Nov 09, 2026 which is in 74 days.
How were Aurobindo Pharma Ltd’s earnings last quarter?
Aurobindo Pharma Ltd released its earnings results on Aug 05, 2026. The company reported ₹17.86 earnings per share for the quarter, beating the consensus estimate of ₹17.262 by ₹0.598.
Is Aurobindo Pharma Ltd overvalued?
According to Wall Street analysts Aurobindo Pharma Ltd’s price is currently Overvalued.
Does Aurobindo Pharma Ltd pay dividends?
Aurobindo Pharma Ltd pays a Notavailable dividend of ₹4 which represents an annual dividend yield of 0.25%. See more information on Aurobindo Pharma Ltd dividends here
What is Aurobindo Pharma Ltd’s EPS estimate?
Aurobindo Pharma Ltd’s EPS estimate is 19.11.
How many shares outstanding does Aurobindo Pharma Ltd have?
Aurobindo Pharma Ltd has 575,377,870 shares outstanding.
What happened to Aurobindo Pharma Ltd’s price movement after its last earnings report?
Aurobindo Pharma Ltd reported an EPS of ₹17.86 in its last earnings report, beating expectations of ₹17.262. Following the earnings report the stock price went up 1.869%.
Which hedge fund is a major shareholder of Aurobindo Pharma Ltd?
Currently, no hedge funds are holding shares in IN:AUROPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aurobindo Pharma Ltd
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Technical Analysis
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Sun Pharmaceutical Industries Limited
―
Torrent Pharmaceuticals Ltd
―
Zydus Lifesciences Limited
―